drugset / Trial / NCT03300960

Usefulness of Medroxyprogesterone Acetate in Follicular Phase in Oocyte Donors. Undergoing Ovarian Stimulation

NCT03300960

RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to determine whether Medroxyprogesterone Acetate (MPA) administration in follicular phase prevents premature luteinization with equal efficiency as GnRH antagonists and otains similar clinical results in oocyte donation.

Timeline

Start
2017-10-20
Primary completion
2019-06-25
Completion
2019-06-25

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ganirelix Protein / enzyme biologic 0.25 mg
Subject medroxyprogesterone acetate Other / unclassified 10 mg Oral

Indications